Bispecific Or Bifunctional, Or Multispecific Or Multifunctional, Antibody Or Fragment Thereof Patents (Class 424/136.1)
  • Patent number: 10815308
    Abstract: Bispecific antigen binding molecules (e.g., antibodies) that bind blood clotting factors, factor IXa (FIXa) and factor X (FX), and enhance the FIXa-catalysed activation of FX to FXa. Use of the bispecific antigen binding molecules to control bleeding, by replacing natural cofactor FVIIIa which is deficient in patients with haemophilia A.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: October 27, 2020
    Assignee: KYMAB LIMITED
    Inventors: Wei Wang, E-Chiang Lee, John Kenneth Blackwood, Roberto Magliozzi
  • Patent number: 10787500
    Abstract: Methods for purifying multispecific antibodies on interest (MAIs) that co-engage at least two different antigens or epitopes (also referred to targets, used interchangeably throughout), from compositions comprising the MAI and parental homodimeric antibody species are provided, as well as reagents which may be used to practice such methods.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: September 29, 2020
    Assignee: Adimab, LLC
    Inventors: Juergen Hermann Nett, K. Dane Wittrup, Maximiliano Vasquez
  • Patent number: 10766967
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: September 8, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marina Bacac, Tanja Fauti, Sabine Imhof-Jung, Christian Klein, Stefan Klostermann, Ekkehard Moessner, Michael Molhoj, Christiane Neumann, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana
  • Patent number: 10766958
    Abstract: Provided herein are methods for managing, treating, or preventing vitiligo using proteins that specifically bind to Programmed Death-1 (PD-1) and modulate the expression and/or activity of PD-1.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: September 8, 2020
    Assignee: Celgene Corporation
    Inventor: Garth E. Ringheim
  • Patent number: 10759870
    Abstract: Bispecific antibodies whose FIX activation-inhibiting activity is not elevated and whose FVIII cofactor function-substituting activity is elevated have been successfully discovered.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: September 1, 2020
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Yuri Teranishi, Kazuki Kato, Hikaru Koga, Tomoyuki Igawa, Kazuki Yamaguchi, Tetsuhiro Soeda
  • Patent number: 10751414
    Abstract: Provided herein are methods for managing, treating, or preventing immune disorders, such as autoimmune diseases, using proteins that specifically bind to Programmed Death-1 (PD-1) and modulate the expression and/or activity of PD-1.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: August 25, 2020
    Assignee: Celgene Corporation
    Inventors: Henry H. Chan, Eun Mi Hur, Roli Khattri, Monica Leung, Garth E. Ringheim, Peter H. Schafer
  • Patent number: 10738127
    Abstract: The present invention provides antibodies that target an E-cadherin linker segment, homologous to other segments adjacent to cell membrane in cancer cell shed proteins for diagnosis and therapy of cancers of epithelial origin. We design this peptide based in experimental observations that demonstrate shedding of E-cadherin and extracellular domains of other cell surface proteins during cancer progression and metastasis and based on our observation that a proline residue after transmembrane domain is present in many proteins on the cell surface that are targets for proteolytic processing. The corresponding antibodies were validated in vitro and in vivo using animal models and have showed no toxicity and significant tumor regression for gastric cancer, including potentiation of commercial drug, when utilized in combination.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: August 11, 2020
    Assignee: Veritas Biotecnologia LTDA
    Inventors: Sandra Rodrigues Pereira Faça, Vitor Marcel Faça
  • Patent number: 10688119
    Abstract: The present disclosure relates to inhibitors of proprotein convertase subtilisin-like/kexin type 9 (PCSK9) for the treatment of lipoprotein metabolism disorders.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: June 23, 2020
    Assignee: Aarhus Universitet
    Inventors: Camilla Gustafsen, Peder Sondergaard Madsen, Simon Glerup Pedersen
  • Patent number: 10683353
    Abstract: Disclosed herein are immunoglobulin fusion proteins comprising a first antibody region, a first therapeutic agent, and a first connecting peptide; wherein the first therapeutic agent is attached to the first antibody region by the connecting peptide; and wherein the connecting peptide does not comprise a region having beta strand secondary structure. The connecting peptide may comprise an extender peptide. The extender peptide may have an alpha helical secondary structure. The connecting peptide may comprise a linker peptide. The linker peptide may not comprise any secondary structure. Also disclosed herein are compositions comprising the immunoglobulin fusion proteins and methods for using the immunoglobulin fusion proteins for the treatment or prevention of a disease or condition in a subject.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: June 16, 2020
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Feng Wang, Yong Zhang, Yan Liu, Peter G. Schultz
  • Patent number: 10683351
    Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human DLL3 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising the polynucleotide and a host cell transformed or transfected with the polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of the antibody construct and a kit comprising the antibody construct.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: June 16, 2020
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Tobias Raum, Claudia Blümel, Christoph Dahlhoff, Patrick Hoffmann, Peter Kufer, Ralf Lutterbüse, Elisabeth Nahrwold, Jochen Pendzialek
  • Patent number: 10669350
    Abstract: The invention relates to single domain VHH fragments which specifically bind to and inhibit superoxide dismutase and/or bind to and inhibit catalase and/or bind to and inhibit superoxide dismutase and catalase, in particular for the use in the therapy of tumor diseases.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: June 2, 2020
    Inventors: Georg Bauer, Manfred Motz
  • Patent number: 10640572
    Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: May 5, 2020
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Allen J. Ebens, Jr., Teemu T. Junttila, Robert F. Kelley, Mary A. Mathieu
  • Patent number: 10633457
    Abstract: The present invention relates to multispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies and uses thereof.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: April 28, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Wolfgang Schaefer, Klaus Mayer
  • Patent number: 10633451
    Abstract: The present invention relates to a bispecific (monoclonal) antibody molecule with a first binding domain binding an antigen on CD8+ T-cells that does not naturally occur in and/or on CD8+ T-cells and a second binding domain binding to a tumor specific antigen naturally occurring on the surface of a tumor cell. The bispecific (monoclonal) antibody molecules are particularly useful in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8+ T-cells and/or a T-cell receptor.
    Type: Grant
    Filed: January 24, 2013
    Date of Patent: April 28, 2020
    Assignees: Hoffmann-La Roche Inc., Ludwig-Maximillians-Universität München
    Inventors: Carole Bourquin, Raffaella Castoldi, Stefan Endres, Christian Klein, Sebastian Kobold, Gerhard Niederfellner, Claudio Sustmann
  • Patent number: 10626190
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: April 21, 2020
    Assignee: Amphivena Therapeutics, Inc.
    Inventors: Kristina Ellwanger, Luke Evnin, Judith A. Fox, Ivica Fucek, Jeanmarie Guenot, Stefan Knackmuss, Lori Kunkel, Melvyn Little, Vera Molkenthin, Erich Rajkovic, Uwe Reusch, Claudia Wall, Michael Weichel, Eugene Zhukovsky
  • Patent number: 10611832
    Abstract: Disclosed are methods for the reduction, prevention or treatment of cardiovascular events and/or cardiovascular diseases, including acute cardiovascular disease or chronic cardiovascular disease using anti-IL-1? binding molecules (e.g., IL-1? binding antibodies and fragments thereof). The present disclosure also relates to methods for prevention or treatment of cardiovascular events and/or cardiovascular diseases, including by reducing a cardiovascular event or disease.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: April 7, 2020
    Assignee: XOMA (US) LLC
    Inventors: Patrick J. Scannon, Alan M. Solinger, Jeffrey D. Feldstein
  • Patent number: 10556964
    Abstract: Provided are compositions comprising a MSBODY and a cytotoxic immune cell (e.g., Cytokine-induced killer cell) to form Armed Activated CIK cells (ACCs), wherein the MSBODY comprising a first antigen binding moiety that has specificity for a tumor antigen, and a second antigen binding moiety that binds to the cell. Provided are also methods preparing a composition comprising a MSBODY and a cytotoxic immune cell, and methods for treating patients with CIK cells armed with bispecific antibodies.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: February 11, 2020
    Assignee: Wuhan YZY Biopharma Co., Ltd.
    Inventors: Pengfei Zhou, Tao Wang, Liu Hu, Mi Huang, Lijuan Fang, Yang Liu
  • Patent number: 10543261
    Abstract: The present invention provides a therapeutic or prophylactic agent for cancer, containing an expression vector encoding a chimeric Hepatitis B virus core antigen polypeptide inserted with an amino acid sequence containing a specific epitope of VEGF and/or a specific epitope of angiopoietin-2, wherein the amino acid sequence containing the specific epitope is inserted between the amino acid residues 80 and 81 of the hepatitis B virus core antigen polypeptide.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: January 28, 2020
    Assignees: Osaka University, AnGes, Inc.
    Inventors: Hironori Nakagami, Mariko Kyutoku, Ryuichi Morishita, Hideki Tomioka
  • Patent number: 10538585
    Abstract: Herein are reported anti-ANG2 antibodies. A specific anti-ANG2 antibody comprises (a) a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 20, (b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 21, and (c) a HVR-H3 comprising the amino acid sequence of SEQ ID NO: 23.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: January 21, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Guy Georges, Peter Michael Huelsmann, Hubert Kettenberger, Joerg Moelleken, Michael Molhoj, Joerg Thomas Regula
  • Patent number: 10487150
    Abstract: SIRPabodies comprise an immunoglobulin variable region, which may specifically bind a tumor antigen, viral antigen, etc., fused to a sequence comprising a binding domain of SIRP?. The binding domain of SIRP? comprises at least the N-terminal Ig-like domain of SIRP?, and may further comprise additional SIRP? sequences. The SIRPabodies find use in therapeutic methods that benefit from the combined activity of blocking CD47 activity, and antibody targeting, e.g. in the treatment of cancer, etc. In some specific embodiments, the SIRPabody comprises anti-CD20 activity and a SIRP? binding domain; anti-CD99 and a SIRP? binding domain; or anti-TIM3 activity and a SIRP? binding domain.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: November 26, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Ravindra Majeti, Emily Piccione Griffin
  • Patent number: 10479831
    Abstract: This invention relates to chimeric and humanized antibodies that specifically bind the BCR complex, and particularly chimeric and humanized antibodies to the BCR complex. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: November 19, 2019
    Assignee: MacroGenics, Inc
    Inventors: Leslie S. Johnson, Ling Huang
  • Patent number: 10472427
    Abstract: The invention provides heterodimeric antibodies comprising a first heavy chain comprising a first Fc domain and a single chain Fv region that binds a first antigen. The heterodimeric antibodies also comprise a second heavy chain comprising a second Fc domain, a first variable heavy chain and a first variable light chain, wherein the first and second Fc domains are different.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: November 12, 2019
    Assignee: Xencor, Inc.
    Inventors: John Desjarlais, Gregory Moore, Rumana Rashid, Matthew Bernett
  • Patent number: 10472419
    Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: November 12, 2019
    Assignees: Novartis AG, DANA-FARBER CANCER INSTITUTE, INC., Children's Medical Center Corporation
    Inventors: Catherine Anne Sabatos-Peyton, Barbara Brannetti, Alan S. Harris, Thomas Huber, Thomas Pietzonka, Jennifer Marie Mataraza, Walter A. Blattler, Daniel J. Hicklin, Maximiliano Vasquez, Rosemarie H. DeKruyff, Dale T. Umetsu, Gordon James Freeman, Tiancen Hu, John A. Taraszka, Fangmin Xu
  • Patent number: 10465006
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Grant
    Filed: July 4, 2014
    Date of Patent: November 5, 2019
    Assignee: GENMAB A/S
    Inventors: Edward Van Den Brink, Joost J. Neijssen, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Paul Parren
  • Patent number: 10457732
    Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: October 29, 2019
    Assignee: MEDIMMUNE, LLC
    Inventors: Srinath Kasturirangan, Changshou Gao, Godfrey Rainey, Michelle Morrow, Claire Louise Dobson, Stacey Drabic, Darren Schofield, Gianluca Carlesso, Kristen Pollizzi, Yariv Mazor, Michael Oberst, Scott A. Hammond, Brian Lobo, Prakash Manikwar, Jonathan Seaman, Simon Dovedi, Ronald Herbst
  • Patent number: 10457745
    Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. In some embodiments, such anti-complement C1s antibodies inhibit proteolytic activity of C1s. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: October 29, 2019
    Assignee: Bioverativ USA Inc.
    Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
  • Patent number: 10450382
    Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: October 22, 2019
    Assignee: Bioverativ USA Inc.
    Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
  • Patent number: 10421816
    Abstract: The present invention provides a multivalent antibody or a heavy/light chain component thereof comprising: a heavy chain comprising a constant region fragment, said constant region fragment located between two variable domains which are not a cognate pair, the heavy chain further comprising an Fc region with at least one domain selected from CH2, CH3 and combinations thereof, with the proviso that the heavy chain contains no more than one CH1 domain and only contains two variable domains, and a light chain comprising a constant region fragment located between two variable domains which are not a cognate pair, wherein said heavy and light chains are aligned to provide a first binding site formed by a first cognate pair of variable domains and a second binding site formed by a second cognate pair of variable domains.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: September 24, 2019
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Ralph Adams, Emma Dave, David Paul Humphreys
  • Patent number: 10407501
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: September 10, 2019
    Assignee: GENMAB A/S
    Inventors: Edward Norbert Van Den Brink, Joost J. Neijssen, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Isil Altintas, Paul Parren, Rik Rademaker
  • Patent number: 10385133
    Abstract: The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: August 20, 2019
    Assignee: E.R. Squibb & Sons, L.L.C.
    Inventors: Josephine M. Cardarelli, Alison Witte, Mohan Srinivasan
  • Patent number: 10377810
    Abstract: The present invention provides for a therapeutic cancer treatment using a soluble CD80 fusion protein that binds to PDL1 and inhibits PDL1-PD1 interactions thereby overcoming PDL1-induced immune suppression and restoring T cell activation.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: August 13, 2019
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE COUNTY
    Inventor: Suzanne Ostrand-Rosenberg
  • Patent number: 10323099
    Abstract: Multispecific antibodies based on antibodies that share a common light chain are described herein. The multispecific antibodies include: modified heavy chains having, by domain exchange, a common light chain variable domain VL; and two modified light chains having, by domain exchange, variable heavy chain domains of a first antibody (VH1) and a second antibody (VH2), wherein one light chain is of kappa isotype and one light chain is of lambda isotype. The present invention also relates to methods for the manufacture of such antibodies and their use.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: June 18, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Peter Bruenker, Christiane Neumann, Christian Klein, Ekkehard Moessner, Wolfgang Schaefer
  • Patent number: 10287352
    Abstract: The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: May 14, 2019
    Assignee: HOFFMAN-LA ROCHE INC.
    Inventors: Laura Codarri-Deak, Georg Fertig, Jens Fischer, Christian Klein, Viktor Levitski, Valeria Lifke, Mario Perro, Joerg Thomas Regula, Tilman Schlothauer, Stefan Seeber, Pablo Umana, Ildiko Wuensche, Adrian Zwick
  • Patent number: 10266608
    Abstract: The present invention provides multivalent and multispecific binding proteins that are capable of binding two or more antigens, or two or more epitopes. The present invention also provides methods of making and using such multivalent and multispecific binding proteins, including methods of using such binding proteins for prevention or treatment of various diseases, or for detecting specific antigens in vitro or in vivo.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: April 23, 2019
    Assignee: EpimAb Biotherapeutics, Inc.
    Inventor: Chengbin Wu
  • Patent number: 10191034
    Abstract: A method for assessing the risk of potential adverse effects for a human patient receiving a CD19×CD3 bispecific antibody is provided. The method comprises determining the total B count in the patient, and identifying a B cell number indicative of a patient at risk of potential adverse effects from the antibody. The method further provides a dosing schedule for administering the antibody to the patient identified as at risk of potential adverse effects. Also provided is a pharmaceutical package or kit comprising a first dose and a second dose, and optionally a third dose, of the CD19×CD3 bispecific antibody as defined in the methods/dosage regimen of the disclosure.
    Type: Grant
    Filed: April 30, 2012
    Date of Patent: January 29, 2019
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventor: Dirk Nagorsen
  • Patent number: 10188729
    Abstract: Methods of treating proliferative disorders are described. In particular, combination treatment with a GITR agonist and a PD-1 antagonist are provided.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: January 29, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Gu Danling, Amy M. Beebe
  • Patent number: 10168339
    Abstract: It is an object of the present invention to provide a marker substance capable of accurately determining a risk of developing metabolic syndrome in vivo. That is, the present invention provides the followings: a marker peptide for determining the risk of developing the metabolic syndrome; an antibody or an aptamer bound to the marker peptide for determining the risk of developing the metabolic syndrome; a microarray in which the antibody or the aptamer bound to the marker peptide for determining the risk of developing the metabolic syndrome has been immobilized on a carrier; a method for determining the risk of developing the metabolic syndrome, comprising measuring an amount or the presence or absence of the marker peptide for determining the risk of developing the metabolic syndrome in a biological sample collected from a subject; and a kit for determining the risk of developing the metabolic syndrome, comprising the antibody or the aptamer or comprising the microarray.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: January 1, 2019
    Assignee: LION CORPORATION
    Inventors: Chiyoko Uchiyama, Kei Kurita, Eriko Fukushima, Riichi Maki
  • Patent number: 10081679
    Abstract: The present invention provides compositions comprising anti-CEACAM1 antibodies, compositions comprising antibodies capable of inhibiting or blocking the interaction between PD-1 and its ligands, and methods for their combined use in treating cancer.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: September 25, 2018
    Assignee: CCAM BIOTHERAPEUTICS LTD.
    Inventors: Tehila Ben-Moshe, Yair Sapir, Ilana Mandel, Edna Meilin
  • Patent number: 10077315
    Abstract: A bispecific antibody specifically binding to the two targets human CD3? and human BCMA, wherein the variable domains of one antibody portion are replaced by each other, and characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-?B activation, BAFF-dependent NF-?B activation, and does not alter NF-?B activation without BAFF and APRIL is useful as a therapeutic agent.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: September 18, 2018
    Assignee: ENGMAB SÀRL
    Inventors: Minh Diem Vu, Klaus Strein, Ekkehard Moessner, Ralf Hosse, Oliver Ast, Anne Freimoser-Grundschober, Marina Bacac, Tanja Fauti, Christian Klein, Pablo Umana, Samuel Moser
  • Patent number: 10072081
    Abstract: The disclosure relates to a protein composed of a first polypeptide or polypeptide domain having a first specific binding activity for Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) expressed on a T-cell cell surface and a second specific binding activity for Glucose Transporter 2 (GLUT2) or an extracellular ectodomain thereof expressed on a pancreatic ?-cell surface, wherein binding of the first polypeptide or polypeptide domain to CTLA-4 induces a CTLA-4 specific agonist response in the T-cell, and binding of the second polypeptide or polypeptide domain to GLUT2 or an ectodomain thereof does not inhibit GLUT2 glucose transporter function, wherein said agonist response in the T-cell induces a response that reduces immunoreactivity against pancreatic ?-cells.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: September 11, 2018
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Bellur S. Prabhakar, Chenthamarakshan Vasu, Palash Bhattacharya
  • Patent number: 10072098
    Abstract: Polypeptides are provided that are capable of significantly inhibiting and/or neutralizing P aeruginosa. The polypeptides comprise two or more immunoglobulin single variable domains that are directed against the PcrV protein of P. aeruginosa, wherein the “first” immunoglobulin single variable domain and the “second” immunoglobulin single variable domain have different paratopes.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: September 11, 2018
    Assignee: Ablynx N.V.
    Inventors: Evelyn De Tavernier, Ann Union, Bruno Dombrecht, Guy Hermans, Erika Morizzo
  • Patent number: 10047163
    Abstract: Provided are novel multispecific antibody constructs and multispecific antibody drug conjugates (ADCs), and methods of using such antibodies and ADCs to treat cancer. IgG-like bispecific antibodies have different binding specificities on each arm of the antibody. They are similar in structure to monospecific IgGs in that they contain two heavy chains with VH, CH1, CH2 and CH3 regions, and two light chains with VL and CL regions.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: August 14, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventor: David Liu
  • Patent number: 10000569
    Abstract: An anti-EGFR/anti-HER3 antibody or antigen binding fragment thereof, and a method of preventing and/or treating a cancer using the same.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: June 19, 2018
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Kwang Ho Cheong, Jae Woong Hwang, Seung Hyun Lee, Powei Lin, Mi Young Cho
  • Patent number: 9988611
    Abstract: The invention provides bispecific fusion proteins that inhibit activation of complement pathway and vascular endothelial growth factor (VEGF) pathway and methods for using these fusion proteins.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: June 5, 2018
    Assignees: AP Biosciences, Inc., Innovent Biologics, Inc.
    Inventors: Jeng-Horng Her, Huang-Tsu Chen
  • Patent number: 9970849
    Abstract: An improved method for the preparation of target specific surfaces and uses thereof is described. In particular, the surfaces are bound to mono-specific tetrameric antibody complexes prior to their addition to a sample containing target entities and separating them from non-target entities.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: May 15, 2018
    Assignee: StemCell Technologies Inc.
    Inventor: Andy Isamu Kokaji
  • Patent number: 9958461
    Abstract: The present invention relates to methods and kits for detecting the interaction between a first membrane protein and a second protein in mammalian cells as well as to identify molecules that can disrupt protein to protein interactions. The invention relies on the functional reconstitution of an active human ubiquitin by two inactive fragments upon the interaction of two proteins attached through a linker to the inactive fragments. The reconstituted ubiquitin is then cleaved by human ubiquitin proteases resulting in the release of an artificial transcription factor, which in turn activates a reporter gene transcription. Activation of the reporter gene is indicative of the interaction between the two proteins.
    Type: Grant
    Filed: June 10, 2014
    Date of Patent: May 1, 2018
    Assignee: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
    Inventors: Igor Stagljar, Julia Petschnigg, Bella Groisman
  • Patent number: 9951118
    Abstract: The HIV-specific cytotoxic T lymphocyte (CTL) response is a critical component in controlling HIV replication and is an important part of the ultimate failure to eradicate the virus. Disclosed herein are methods for genetically enhancing the HIV-specific CTL response to allow long-term viral suppression or viral clearance. Human hematopoietic stem cells (HSCs) were genetically modified such that they differentiate into mature CTLs that will kill HIV infected cells. As disclosed herein, the functional effector cells are not human leukocyte antigen (HLA)-restricted. As disclosed herein, stem cells are transduced with non-HLA restricted chimeric antigen receptors (CARs) that allow the recognition of HIV or HIV-infected cells when expressed by a CTL. These CARs are hybrid molecules that contain an extracellular HIV recognition domain and an intracellular TCR-zeta signaling domain. The CTL response may be enhanced through the targeting of T cell inhibitory receptors.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: April 24, 2018
    Assignee: The Regents of the University of California
    Inventors: Scott G. Kitchen, Jerome A. Zack, Otto O. Yang, Irvin Chen, Masakazu Kamata
  • Patent number: 9944709
    Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a CD123 monoclonal antibody, conferring specific immunity against CD123 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: April 17, 2018
    Assignee: CELLECTIS
    Inventor: Roman Galetto
  • Patent number: 9915665
    Abstract: System and methods are disclosed for identifying and isolating antibodies with specific affinity with an antigen of interest. Multiple DNA libraries encoding antibodies or their fragments are designed such that the encoded antibodies from different libraries are tagged differently. These libraries may be transformed into yeast cells. The variants of the antibodies are displayed on the surface of the yeast cells and flow cytometry may be used to sort the cells based on antigen affinity and the different tags on the antibodies. By allowing multiple libraries to be screened simultaneously, the disclosed methods help improve the efficiency of affinity.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: March 13, 2018
    Assignee: ABBVIE INC.
    Inventors: Lorenzo Benatuil, Jennifer Perez, Chung-Ming Hsieh
  • Patent number: 9914776
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: March 13, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Oliver Ast, Marina Bacac, Sabine Imhof-Jung, Christiane Jaeger, Christian Klein, Stefan Klostermann, Michael Molhoj, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana